Stock Price
2.96
Daily Change
-0.03 -1.00%
Monthly
1.37%
Yearly
-32.03%
Q2 Forecast
3.03

MannKind reported $548.07M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Adma Biologics USD 193.58M 124.25M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Insmed USD 542.22M 1.25M Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
MacroGenics USD 70M 256K Dec/2025
MannKind USD 548.07M 371K Mar/2026
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Novavax USD 246.3M 200K Dec/2025
Novo Nordisk DKK 14.02B 224.49M Sep/2025
Pfizer USD 60.57B 1.08B Mar/2026
Sanofi EUR 13.84B 1.88B Mar/2026
Xencor USD 82.12M 5.64M Mar/2026